

# Ordering hydroxychloroquine at KHN

The dose is hydroxychloroquine is 400 mg BID x2 doses, then 400 mg QD x4 days (five days total)

Ordering in Epic will be a modification of current panel with guidance and 2 order questions

- QTc < 500? (most recent QTc will be displayed)
- Meets criteria for administering HCQ (criteria will be displayed, *see next slides*)

**The team is aware that most patients that meet admission criteria are candidates for HCQ**

This fits with the intention of preventing progression of disease to the critical phase of respiratory failure

**Hydroxychloroquine is in very short supply. Clinicians are expected to follow these guidelines.**

## Indications for hydroxychloroquine When SARS CoV-2 status is pending

**Patients with fever (temp > 100.4), cough, SOB and two (2) of:**

- Age > 65
- Cardiovascular disease, excluding hypertension as a sole cardiovascular diagnosis
- Diabetes with A1c level >7.5%
- Chronic pulmonary diseases, including asthma
- End-stage renal disease
- Advanced liver disease
- Blood disorders (e.g., sickle cell disease)
- Neurologic or neurodevelopmental disorders
- Post–solid organ transplantation, on immunosuppressive therapy
- Use of biologic agents for immunosuppression
- Undergoing treatment with chemotherapy or immunotherapies for malignancy
- Within 1 year post–marrow transplant
- Undergoing treatment for graft-versus-host disease
- HIV infection, with CD4 cell count <200 copies/mm<sup>3</sup>
  
- Critical illness as measured by CURB65  $\geq 2$
  
- O<sub>2</sub> sat < 92% on room air ( or their usual home O<sub>2</sub> )

## Indications for hydroxychloroquine When SARS-CoV-2 is positive

### Any one (1) of :

- Age > 65
- Cardiovascular disease, excluding hypertension as a sole cardiovascular diagnosis
- Diabetes with A1c level >7.5%
- Chronic pulmonary diseases, including asthma
- End-stage renal disease
- Advanced liver disease
- Blood disorders (e.g., sickle cell disease)
- Neurologic or neurodevelopmental disorders
- Post–solid organ transplantation, on immunosuppressive therapy
- Use of biologic agents for immunosuppression
- Undergoing treatment with chemotherapy or immunotherapies for malignancy
- Within 1 year post–marrow transplant
- Undergoing treatment for graft-versus-host disease
- HIV infection, with CD4 cell count <200 copies/mm<sup>3</sup>
- Critical illness as measured by CURB65  $\geq 2$
- O<sub>2</sub> sat < 92% on room air ( or their usual home O<sub>2</sub> )

## Exclusions for hydroxychloroquine

- Pregnancy / breastfeeding
  - Evidence of fetal harm with HCQ, consult ID
- Terminal illness
  - Exclusive of COVID-19
- Previous course of HCQ
  - Consult with pharmacy / ID for exception
- Seizure disorder
- Retinopathy
- Weight less than 50 kg
- QTc > 500

Above represents synthesis of

- KHN ID
- KHN cardiology
- Johns Hopkins
- Mass General
- University of Washington
- UpToDate (multiple citations)
- BARDA letter ( strategic national stockpile release of HCQ )

For patients with QTc 450-500, then ECG in 3 days.